Current Status of Immunotherapy for B-cell Lymphoma

Although the first-line treatment regimens represented by R-CHOP have shown good efficacy in B-cell lymphoma, there are still some patients with recurrence and progression. With the advent of the era of tumor immunotherapy, the immunotherapy of B-cell lymphoma has been rapidly developed, including immune checkpoint inhibitors, CAR-cell, tumor microenvironment regulation, etc. This article reviews the current status of immunotherapy of B-cell lymphoma.